Undeterred by last year’s rejection and the recent approval of a close rival from Pfizer, Novo Nordisk has pushed its ...

Novo Nordisk (NVO) wins U.S. FDA nod for its Alhemo injection as a once-daily prophylaxis for bleeding prevention in patients ...

Denmark’s Novo Nordisk said late Friday that the US Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) ...

The task ahead of Vertex now is to migrate patients already on Trikafta to the new drug. That is supported by data from the ...

Plainsboro: Novo Nordisk has announced that the U.S. Food and Drug Administration (FDA) has approved Alhemo (concizumab-mtci) ...

The approval of concizumab-mtci (Alhemo) injection marks a significant milestone in managing hemophilia A and B with ...

With Alhemo (concizumab-mtci) from Novo Nordisk A/S, a third hemophilia drug in the past eight months has been approved by the U.S. FDA. The once-daily injectable prophylaxis is to prevent or reduce ...

The FDA initially rejected the marketing application for Alhemo in 2022, asking for additional data on dosing and monitoring.

Novo Nordisk (NVO) announced that the U.S. Food and Drug Administration (FDA) has approved its Alhemo (concizumab-mtci) bleeding prevention injection for patients with rare clotting disorders ...

recommending the approval of Alhemo (concizumab) for haemophilia A or B with inhibitors. A final decision is expected soon. Alhemo is not approved in the United States. Novo Nordisk is trading ...